FDA Orders Azurity Pharmaceuticals to Halt Distribution of Unapproved Compounding Kits
The FDA has mandated Azurity Pharmaceuticals Inc. to cease the distribution of unapproved drugs in their compounding kits.
Therapeutic Area
Therapeutic area intelligence for Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.